Lisinopril: Effective Blood Pressure and Heart Failure Management
Lisinopril
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $1.13 | $68.00 (0%) | 🛒 Add to cart |
| 90 | $0.96 | $102.00 $86.00 (16%) | 🛒 Add to cart |
| 120 | $0.87 | $136.00 $104.00 (24%) | 🛒 Add to cart |
| 180 | $0.78 | $204.00 $140.00 (31%) | 🛒 Add to cart |
| 270 | $0.72 | $306.00 $194.00 (37%) | 🛒 Add to cart |
| 360 |
$0.69
Best per pill
|
$408.00 $248.00 (39%) | 🛒 Add to cart |
| Product dosage: 2.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.49 | $44.00 (0%) | 🛒 Add to cart |
| 180 | $0.41 | $88.00 $74.00 (16%) | 🛒 Add to cart |
| 270 | $0.38 | $132.00 $103.00 (22%) | 🛒 Add to cart |
| 360 |
$0.37
Best per pill
|
$176.00 $133.00 (24%) | 🛒 Add to cart |
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor prescribed primarily for the management of hypertension, heart failure, and post-myocardial infarction care. It works by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby promoting vasodilation and reducing afterload. This medication is widely recognized for its cardioprotective benefits, including slowing the progression of renal disease in diabetic patients. Available in oral tablet form, it is typically administered once daily due to its prolonged half-life and consistent antihypertensive effect.
Features
- Active ingredient: Lisinopril
- Drug class: Angiotensin-converting enzyme (ACE) inhibitor
- Available strengths: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg tablets
- Administration: Oral, once-daily dosing
- Onset of action: Within 1 hour; peak effect at 6 hours
- Half-life: 12 hours
- Excretion: Primarily renal
Benefits
- Effectively lowers blood pressure, reducing risk of stroke, myocardial infarction, and other cardiovascular events
- Improves survival rates and symptom management in patients with congestive heart failure
- Demonstrates renal protective effects, particularly in diabetic patients with proteinuria
- Once-daily dosing supports medication adherence and consistent therapeutic coverage
- Well-tolerated profile with a lower incidence of metabolic side effects compared to some other antihypertensives
Common use
Lisinopril is indicated for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents. It is also used in the management of symptomatic heart failure, often as adjunctive therapy with diuretics and/or beta-blockers. Additionally, lisinopril is prescribed to improve survival following acute myocardial infarction in hemodynamically stable patients. Off-label uses may include the prevention of diabetic nephropathy and reduction of proteinuria in certain patient populations.
Dosage and direction
For hypertension, the initial dose is typically 10 mg once daily, which may be adjusted based on blood pressure response, up to a maximum of 40 mg daily. In heart failure, treatment usually begins with 2.5–5 mg once daily under close medical supervision, with gradual titration as tolerated. Post-myocardial infarction patients may start with 5 mg within 24 hours of the event, followed by 5 mg after 24 hours, 10 mg after 48 hours, and then 10 mg daily. Dosage adjustments are necessary in patients with renal impairment. Administration should occur at approximately the same time each day, with or without food.
Precautions
Patients should be monitored for hypotension, especially during initial dosing and titration periods. Renal function and serum potassium levels require regular assessment, particularly in patients with pre-existing renal impairment, diabetes, or those using potassium-sparing diuretics. Angioedema, though rare, may occur and requires immediate discontinuation and medical attention. Use with caution in patients with collagen vascular disease or those receiving immunosuppressive therapy due to increased risk of neutropenia/agranulocytosis. Pregnancy must be avoided during treatment due to potential fetal harm.
Contraindications
Lisinopril is contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy or hereditary/idiopathic angioedema. It should not be used in patients with hypersensitivity to lisinopril or any other ACE inhibitor. Concomitant use with aliskiren in patients with diabetes is contraindicated. The medication is also contraindicated during the second and third trimesters of pregnancy.
Possible side effect
Common adverse reactions include dizziness (6–12%), headache (5–9%), cough (up to 35%), fatigue (3–6%), and nausea (2–5%). Less frequently, orthostatic hypotension, hyperkalemia, rash, and impaired renal function may occur. Serious but rare side effects include angioedema (0.1–0.7%), neutropenia/agranulocytosis, hepatic failure, and pancreatitis. The characteristic dry, persistent cough is often treatment-limiting and may necessitate switching to an alternative antihypertensive class.
Drug interaction
Lisinopril may interact with diuretics, potentiating hypotensive effects. Concurrent use with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium increases the risk of hyperkalemia. Nonsteroidal anti-inflammatory drugs (NSAIDs) may diminish the antihypertensive effect and increase renal impairment risk. Lithium levels may increase with concomitant ACE inhibitor use. Dual blockade of the renin-angiotensin system with ARBs or aliskiren is not recommended due to increased risks of hypotension, hyperkalemia, and renal impairment.
Missed dose
If a dose is missed, it should be taken as soon as possible on the same day. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. Patients should not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining stable blood pressure control, but occasional missed doses are unlikely to cause significant therapeutic compromise.
Overdose
Lisinopril overdose may manifest as severe hypotension, which can progress to shock. Bradycardia, electrolyte disturbances (particularly hyperkalemia), and renal failure may also occur. Management is primarily supportive, including volume expansion with intravenous normal saline for hypotension. Atropine may be administered for bradycardia. Hemodialysis may be effective in removing lisinopril from the systemic circulation. Serum electrolyte levels and renal function should be closely monitored.
Storage
Store at controlled room temperature (20–25°C or 68–77°F) in a tightly closed container. Protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations, typically through medication take-back programs rather than flushing or household trash disposal.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient responses to lisinopril may vary based on clinical circumstances, comorbidities, and concomitant medications. Dosage and treatment decisions should be made exclusively by qualified healthcare professionals familiar with the patient’s complete medical history. Never initiate, adjust, or discontinue medication without consulting a physician.
Reviews
Clinical trials and meta-analyses consistently demonstrate lisinopril’s efficacy in blood pressure reduction and cardiovascular risk modification. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) established lisinopril as an effective first-line antihypertensive, though with slightly less stroke prevention compared to diuretics in some subgroups. The SOLVD treatment trial showed significant mortality reduction in heart failure patients. Many clinicians appreciate its once-daily dosing and generally favorable side effect profile, though the characteristic ACE inhibitor cough remains a notable limitation for some patients. Real-world evidence supports its cost-effectiveness and reliable performance in diverse patient populations.